Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you're based in Northampton and looking into weight loss injections, here is the direct answer: both Mounjaro (tirzepatide) and Wegovy (semaglutide) are licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition. They are prescription-only medicines, which means a qualified prescriber must assess your suitability before any treatment can be dispensed — regardless of where you live. Northampton residents can access either medicine through a regulated UK weight loss injection service online, with no need to travel to a clinic.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Both Mounjaro and Wegovy belong to the GLP-1 class of medicines. GLP-1 is a gut hormone released after eating; these medicines mimic it, acting on receptors in the brain and gut to reduce appetite, increase feelings of fullness, and slow the rate at which food leaves the stomach. Mounjaro goes a step further. It also activates the GIP receptor (a second gut-hormone pathway involved in blood-sugar regulation and energy balance) which is why it is described as a dual agonist and why its trial results tend to be stronger. In SURMOUNT-1, a 72-week clinical trial published in the New England Journal of Medicine, participants taking tirzepatide 15mg lost an average of around 20–21% of their body weight. Wegovy's STEP 1 trial showed an average reduction of around 15% at 2.4mg over 68 weeks. These are population averages from controlled trials, not guarantees, individual results vary, and a prescriber will set realistic expectations during your consultation.
The injections do not burn fat directly. They change the hormonal signals that govern hunger and satiety, which makes it easier to eat less without fighting constant cravings. Many people find the changes gradual in the first few weeks, becoming more noticeable as the dose increases.
Eligibility follows the medicines' UK licences, not geography. For Mounjaro, the licensed threshold is a BMI of 30 or above, or 27 or above if you have at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnoea or osteoarthritis. Wegovy carries the same BMI thresholds. For some ethnic backgrounds (including South Asian, Chinese, Middle Eastern, Black African and African-Caribbean) UK guidance sets the qualifying thresholds 2.5 kg/m² lower. BMI alone is not the whole picture; the prescriber looks at your full health history, current medicines, and any conditions that might make treatment unsuitable. You can get a sense of where you stand using the NHS BMI calculator before you start. Pregnancy, breastfeeding, or actively trying to conceive rule out both medicines; neither is licensed for anyone under 18.
NHS access to these medicines in Northampton follows the national phased rollout, which has strict criteria around BMI, the number of qualifying conditions, and referral to specialist weight management services. Many people who are clinically suitable do not yet meet the NHS phase criteria or face long waits. A private prescription through a regulated online pharmacy is the legal alternative, the same medicines, the same clinical assessment, without a referral.
The side-effect profile of both medicines is well documented. Gastrointestinal effects are the most common: nausea, loose stools, constipation, bloating, indigestion and, less often, vomiting. These are typically most noticeable after starting treatment or stepping up to a higher dose, and they tend to settle within days to a couple of weeks as the body adjusts. Injection-site reactions, fatigue and mild headache are also reported. The slow titration schedule (treatment begins at a low starter dose and increases gradually) exists largely to give the body time to adapt and to keep side effects manageable.
One side effect worth knowing about in detail: the MHRA highlighted acute pancreatitis as an infrequent but potentially serious risk associated with GLP-1 medicines. Severe, persistent stomach pain that spreads to the back, with or without vomiting, warrants urgent medical attention. The NHS medicines page for tirzepatide (Mounjaro) sets out the full list of side effects and when to seek help. Patients can also report any suspected side effect directly to the MHRA at yellowcard.mhra.gov.uk. If you are taking oral contraceptives and start Mounjaro, your prescriber will advise adding a barrier method for the first four weeks of treatment and after each dose increase, because slowed gastric emptying may reduce absorption of the pill.
For a fuller picture of what these injections involve (including storage, technique and what to do about a missed dose) the weight loss injection guide covers the practicalities in detail.
This is the question most Northampton residents actually want answered. The process at a regulated UK online pharmacy starts with a free consultation, a structured clinical questionnaire covering your BMI, health history, current medications and goals. A real prescriber reads your answers and, if treatment is clinically suitable, issues a prescription. No algorithm makes that call. Identity and weight are verified, and your GP is notified in line with GPhC guidance.
Once approved, the pen is dispatched from a GPhC-registered UK pharmacy the same day if your consultation is submitted before midday on a working day. It arrives the next working day with DPD, trackable on your phone, in a plain box with no indication of what's inside. The pen itself is a pre-filled device; each KwikPen contains four weekly doses, kept in the fridge at home. There are no subscription traps, every repeat order is reviewed again before it is dispensed. Questions about pricing and what private treatment costs are worth reading before you decide, since headline prices can vary considerably and do not always include prescription fees, clinical reviews or aftercare.
Our clinical team and the pharmacy are GPhC-registered and verifiable on the GPhC register (premises registration 9012878). If you want to read about the full range of options before starting, the weight loss overview is a useful starting point, and patients in other parts of the country can find locally relevant information, for example if you are looking into weight loss injections in Southampton, weight loss injections in Northern Ireland, or curious about approaches such as lemon injections for weight loss, those pages cover what you need to know. When you are ready, check your eligibility with a free consultation and a prescriber will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.